Celltrion's Infliximab, The First Monoclonal Antibody Biosimilar, Is Now Remdantry™ In Canada
Toronto, ON (BUSINESS WIRE) - Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name RemdantryTM starting April 1, 2025, following approval of the …